JATT Acquisition Corp. (NYSE: JATT) is a Special Purpose Acquisition Company (“SPAC”), with a focus on the Life Sciences sector

Last Updated : Wednesday October 20, 2021

JATT Acquisition Corp. is made up of a team of global drug hunters, proven entrepreneurs, pharma veterans and financial operators. With several decades of combined experience and successful multi-billion dollar deals, we have honed our formula to unlock future value powered by deep sector and capital markets knowledge.

 
 

Our Focus

Our company intends to focus its search primarily in the life sciences sector, particularly businesses within

Intersection of AI and mechanistic genetics

Therapeutic areas of interest; immunology, oncology, rare disease

With attractive and promising clinical stage assets that target unmet medical needs and are near an inflection point in value creation.

Expertise

JATT has repeated success in realizing value inflection points from early R+D through commercialization to meet unmet medical needs

Network

JATT has global experts in identifying high-value assets with an exceptional proprietary international network

Capital Markets

JATT possesses a deep understanding of identifying assets that are well-received in private and public markets and in helping assets into public markets

Deal Making

JATT has a track-record of profitable deal-making and successfully executing M&A, partnership deals, cross-over rounds and public market deals.

ROI

JATT has a team that has a strong track record in delivering value and generating ROI for investors

Meet the Team

Dr. Someit Sidhu

Founder, CEO & Director
Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics

Tauhid Ali ,PhD

COO & Director
Former EVP at Cambrian Biopharma and Head of Rare Disease Strategy & Founder of TAKcelerator™ at Takeda

Verender S. Badial

CFO
Former MD in ECM at Société Générale and ABN AMRO Rothschild
Founder of Cryfield Investments

Graeme Sloan

General Counsel
Former Global Co-Head of M&A at Morrison & Foerster LLP, former global Co-Chair of M&A at Latham & Watkins LLP, Co-Chair of Lex Mundi cross border transaction group

Arnout Ploos van Amstel

Director
Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis

Javier Cote‐Sierra, PhD

Director
Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme

Yuan-Hua Ding, PhD

Advisor
Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs

Investor Relations

Price updates

SEC Filings

Click Here

JATT News

Click here

Price updates

SEC Filings

Click Here

JATT News